A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Trial Profile

A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jan 2017

At a glance

  • Drugs Tazarotene/ulobetasol (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Valeant Pharmaceuticals International
  • Most Recent Events

    • 10 Jan 2017 Primary endpoint has been met. (Treatment success rate), as reported by a Valeant Pharmaceuticals International Media Release.
    • 10 Jan 2017 Results published in the Valeant Pharmaceuticals International Media Release
    • 08 Dec 2016 According to a Valeant Pharmaceuticals media release, company expects to have data from this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top